PCOS. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: In this study, auriculotherapy is used as a non-invasive and side-effect-free treatment method. This approach is based on stimulating specific points on the ear usi
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Willingness to participate in the study Couple's desire to get pregnant Primary infertility Normal spermogram Not taking drugs such as clomiphene citrate and letrozole Infertility due to ovulation disorder Absence of structural and anatomical disorders of the uterus such as polyps, myomas, malformations of the Müllerian system, etc. Not suffering from any uncontrolled underlying disease (diabetes, hypertension, lupus, etc.) 18.5-29.9= BMI Failure to use certain drugs (hormonal drugs, drugs related to the underlying disease) during the last three months Non-use of complementary and alternative medicine methods and traditional medicine during the last three months No addiction Absence of any mass, inflammation, or infection in the ears The scores of depression, anxiety, and stress are less than 21, 15, and 26, respectively
Exclusion criteria
Exclusion criteria: Secondary infertility Abnormal spermogram Taking any medication related to the underlying disease and hormonal treatments during the last 3 months Infertility with causes other than ovulation disorders Suffering from structural and anatomical disorders of the uterus such as polyps, myomas, malformations of the Müllerian system, etc. Having any uncontrolled underlying disease (diabetes, hypertension, lupus, etc.) BMI>30 Application of complementary and alternative medicine methods and traditional medicine during the last three months Presence of any mass, inflammation, or infection in the ears
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Follicle Stimulating Hormone. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ELISA(lU/L).;Luteinizing Hormone. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ELISA(lU/L).;Anti-Müllerian Hormone. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ELISA(ng/ml).;Number of follicles. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ultrasound (number).;Follicle size. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ultrasound (number (mm)).;Ovary volume. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ultrasound(cm³).;Endometrial thickness. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ultrasound(mm).;Beta-Human Chorionic Gonadotropin. Timepoint: After completing the intervention. Method of measurement: ELISA( mIU/mL).;Length of menstrual cycle. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: day.;Hirsutism. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: Ferriman-Gallwey Score.;Acne. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: Global Acne Grading System.;Menstrual irregularity. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: Questionnaire (yes-no).;E2 hormone. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: ELISA (pg/mL).;Dehydroepiandrosterone Sulfate hormone. Timepoint: Before the intervention, immediately and | — |
Secondary
| Measure | Time frame |
|---|---|
| Stress. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: DAS-21 (Depression Anxiety Stress).;Anxiety. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: DAS-21 (Depression Anxiety Stress).;Depression. Timepoint: Before the intervention, immediately and three months after the intervention. Method of measurement: DAS-21 (Depression Anxiety Stress). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahereh Heydarian
Esfahan University of Medical Sciences
Outcome results
None listed